Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with <sup>18</sup>F-FDG and <sup>89</sup>Zr-Trastuzumab PET
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Jason S. Lewis(Memorial Sloan Kettering Cancer Center)
Cited by 93
Related Papers
1-<sup>11</sup>C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
|Journal of Nuclear Medicine|2008|154
Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
|PLoS ONE|2010|129
Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
|Nature Communications|2022|40
Noninvasive <sup>89</sup> Zr-Transferrin PET Shows Improved Tumor Targeting Compared with <sup>18</sup> F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer
|Journal of Nuclear Medicine|2017|37
Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
|Journal of Nuclear Medicine|2019|32